Long-Term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial
Patients with Dravet syndrome were treated with varying doses of CBD.
During the 48 weeks of treatment, monthly total seizure frequency reduced by 51%.
After the 48 weeks of treatment, 85% of patients/caregivers reported improvement of
the patient’s overall condition. Common adverse effects included diarrhea, pyrexia (fever),
decreased appetite, and somnolence (strong desire to sleep).